Targeted screening of individuals at high risk for pancreatic cancer: Results of a simulation model

Radiology

Volumn 275, Issue 1, 2015, Pages 177-187

  Pandharipande, Pari V ^a   Heberle, Curtis ^a   Dowling, Emily C ^a   Kong, Chung Yin ^a   Tramontano, Angela ^a   Perzan, Katherine E ^a,b   Brugge, William ^a,b   Hur, Chin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FALSE POSITIVE RESULT; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS DUCT; PANCREAS DUCTAL ADENOCARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIMULATION; STATISTICAL MODEL; SURGICAL MORTALITY; CALIBRATION; COMPUTER SIMULATION; DISEASE COURSE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MARKOV CHAIN; MASS SCREENING; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PREVALENCE; PROCEDURES; RISK;

CALIBRATION; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; COMPUTER SIMULATION; DISEASE PROGRESSION; FEMALE; HUMANS; LIFE EXPECTANCY; MAGNETIC RESONANCE IMAGING; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; PANCREATIC NEOPLASMS; PREVALENCE; RISK; SENSITIVITY AND SPECIFICITY;

EID: 84926451694     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14141282     Document Type: Article

References (63)

1. American Cancer Society. Cancer facts and figures 2013. Atlanta, Ga: American Cancer Society, 2013.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74(11):2913-2921.
3. Howlader N, Noone AM, Krapcho M, et al, eds. SEER cancer statistics review, 1975-2010, National Cancer Institute. Bethesda, Md, http://seer.cancer.gov/csr/1975-2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Accessed September 6, 2013.
4. Key C. Cancer of the pancreas. In: Ries LAG, Young JL Jr, Keel GE, Eisner MP, Lin YD, Horner MJD, eds. SEER survival monograph: cancer survival among adults: U. S. SEER program, 1988-2001, patient and tumor characteristics. National Cancer Institute, SEER program, NIH pub. no. 07-6215. Bethesda, Md: National Cancer Institute, 2007.
5. Brugge WR, Lauwers GY, Sahani D, Fernandez-Del Castillo C, Warshaw AL. Cystic neoplasms of the pancreas. N Engl J Med 2004;351(12):1218-1226.
6. Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8(9):972-1017.
7. Shin EJ, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am 2012;41(1):143-157.
8. Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol 2008;191(3):802-807.
9. Lee KS, Sekhar A, Rofsky NM, Pedrosa I. Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol 2010;105(9):2079-2084.
10. Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013;258(3):466-475.
11. Lafemina J, Katabi N, Klimstra D, et al. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. Ann Surg Oncol 2013;20(2):440-447.
12. Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 2012;16(4):771-783.
13. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2(7):606-621.
14. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62(3):339-347.
15. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012;142(4):796-804; quiz e14-e15.
16. Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002;56 (4, Suppl):S82-S86.
17. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009;58(10):1410-1418.
18. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011;106(5):946-954.
19. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009;104(9):2175-2181.
20. Schneider R, Slater EP, Sina M, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 2011;10(2):323-330.
21. Vasen HF, Wasser M, Van Mil A, et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011;140(3):850-856.
22. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010;16(20):5028-5037.
23. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999;131(4):247-255.
24. Steinberg WM, Barkin JS, Bradley EL III, et al. Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas? Pancreas 2009;38(5):e137-e150.
25. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139(4):1076-1080, 1080.e1-e2.
26. Jimenez RE, Fernandez-Del Castillo C. Tumors of the pancreas. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's gastrointestinal and liver disease. 9th ed. Philadelphia, Pa: Saunders Elsevier, 2010;1017-1034.
27. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64(7):2634-2638.
28. Templeton AW, Brentnall TA. Screening and surgical outcomes of familial pancreatic cancer. Surg Clin North Am 2013;93(3):629-645.
29. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006;4(6):766-781; quiz 665.
30. De Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U. S. Preventive Services Task Force. Ann Intern Med 2014;160(5):311-320.
31. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 2003;48(7):1273-1283.
32. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004;96(4):316-325.
33. Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012;157(9):611-620.
34. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011;6(11):1841-1848.
35. McMahon PM, Kong CY, Johnson BE, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 2008;248(1):278-287.
36. McMahon PM, Kong CY, Johnson BE, et al. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal 2012;32(Suppl 1):S117-S124.
37. Rutter CM, Knudsen AB, Pandharipande PV. Computer disease simulation models: integrating evidence for health policy. Acad Radiol 2011;18(9):1077-1086.
38. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73(6):883-888.
39. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3(4):419-458.
40. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982;73(6):889-897.
41. Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12(3):183-197.
42. Pellegrini CA, Heck CF, Raper S, Way LW. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg 1989;124(7):778-781.
43. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206(3):358-365.
44. Fernández-del Castillo C, Morales-Oyarvide V, McGrath D, et al. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery 2012;152 (3, Suppl 1):S56-S63.
45. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 2011;364(22):2128-2137.
46. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10(9):1199-1210; discussion 1210-1211.
47. Reames BN, Ghaferi AA, Birkmeyer JD, Dimick JB. Hospital volume and operative mortality in the modern era. Ann Surg doi: 10.1097/SLA.0000000000000375. Published online December 13, 2013
48. Arias E. United States life tables, 2008. In: National vital statistics reports. Volume 61, number 3. Hyattsville, Md: National Center for Health Statistics, 2012.
49. Surveillance, Epidemiology, and End Results Results (SEER) Program DevCan database. SEER 18 incidence and mortality, 2000-2010, with Kaposi sarcoma and mesothelioma. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released June 2013, based on the November 2012 submission. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Accessed August 22, 2013.
50. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 2009;27(7):533-545.
51. Baron TH, Mallery JS, Hirota WK, et al. The role of endoscopy in the evaluation and treatment of patients with pancreaticobiliary malignancy. Gastrointest Endosc 2003;58(5):643-649.
52. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 1998;339(6):380-386.
53. Van Ravesteyn NT, Miglioretti DL, Stout NK, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med 2012;156(9):609-617.
54. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, Van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U. S. Preventive Services Task Force. Ann Intern Med 2008;149(9):659-669.
55. Hur C, Hayeck TJ, Yeh JM, et al. Development, calibration, and validation of a U. S. white male population-based simulation model of esophageal adenocarcinoma. PLoS ONE 2010;5(3):e9483.
56. Yeh JM, Kuntz KM, Ezzati M, Hur C, Kong CY, Goldie SJ. Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 2008;17(5):1179-1187.
57. Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 2003;57(1):23-29.
58. Sipos B, Frank S, Gress T, Hahn S, Klöppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 2009;9(1-2):45-54.
59. Fernández-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138(4):427-433; discussion 433-434.
60. Onega T, Beaber EF, Sprague BL, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer 2014;120(19):2955-2964.
61. Nehra D, Oyarvide VM, Mino-Kenudson M, et al. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Pancreatology 2012;12(4):358-363.
62. Yu M, Ting DT, Stott SL, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487(7408):510-513.
63. Harinck F, Nagtegaal T, Kluijt I, et al. Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med 2011;13(12):1015-1024.